Lisa A. Jackson, MD, MPH, is an internist and infectious disease epidemiologist who has conducted clinical and epidemiologic studies of vaccine safety and efficacy since 1991.
Dr. Jackson is the principal investigator (PI) of KPWHRI’s Vaccine and Treatment Evaluation Unit — one of 10 network sites that the National Institutes of Health (NIH) sponsors. In this role, she leads the phase 1 clinical trial of the COVID-19 vaccine co-developed by Moderna and NIH. Launched in March 2020, this trial was the first in the world to begin testing a COVID-19 vaccine. She is also leading the phase 3 clinical trials of the COVID-19 vaccines developed by Moderna and NIH and by Janssen Pharmaceutical Companies, part of Johnson & Johnson, at KPWHRI.
Additionally, Dr. Jackson serves as KPWHRI’s principal investigator in the Vaccine Safety Datalink Project (VSDP). Sponsored by the Centers for Disease Control and Prevention (CDC), VSDP conducts ongoing research on the safety of licensed vaccines in routine use.
Dr. Jackson has written more than 200 peer-reviewed publications and 14 book chapters. She is a past member of the Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee and the National Vaccine Program Office’s National Vaccine Advisory Committee.
After receiving her medical degree from the University of Virginia School of Medicine, in Charlottesville, Dr. Jackson earned her Master of Public Health (MPH) degree at the University of Washington (UW) School of Public Health. She completed her internal medicine residency training at the UW School of Medicine and served as an epidemic intelligence officer and preventive medicine resident at the CDC.
Vaccine safety; COVID-19 vaccine safety and effectiveness; influenza vaccine effectiveness in the elderly; methodologic issues in vaccine effectiveness evaluations; pneumococcal polysaccharide vaccine effectiveness; pneumococcal conjugate vaccine immunogenicity in the elderly; epidemiology of E. coli bacteremia; epidemiology of community-acquired pneumonia
Pearson D, Jackson LA, Winkler B, Foss B, Wagener B. Use of an automated pharmacy system and patient registries to recruit HMO enrollees for an influenza campaign. Eff Clin Pract. 1999;2(1):17-22. PubMed
Jackson LA, Grayston JT. Chlamydia pneumoniae. In: Yu VL, Merigan TC Jr, Barriere, eds. Antimicrobial Therapy and Vaccines. Baltimore: Williams & Wilkins, 1999:583-586.
Pearson DC, Jackson LA, Wagener B, Sarver L. A comprehensive influenza campaign in a managed care setting. Vaccine. 1998;16(18):1718-21. PubMed
Smith WJ, Jackson LA, Watts DH, Koepsell TD. Prevention of chickenpox in reproductive-age women: cost-effectiveness of routine prenatal screening with postpartum vaccination of susceptible. Obstet Gynecol. 1998;92(4 Pt 1):535-45. PubMed
Parashar UD, Holman RC, Bresee JS, Clarke MJ, Rhodes PH, Davis RL, Thompson RS, Mullooly JP, Black SB, Shinefield HR, Marcy SM, Vadheim CM, Ward JI, Chen RT, Glass RI. Epidemiology of diarrheal disease among children enrolled in four West Coast health maintenance organizations. Vaccine Safety Datalink Team. Pediatr Infect Dis J. 1998;17(7):605-11. PubMed
Jackson LA. Infections and atherosclerotic cardiovascular disease. Infect Med. 1998;15:480.
Cordell RL, MacDonald JK, Solomon SL, Jackson LA, Boase J. Illnesses and absences due to illness among children attending child care facilities in Seattle-King County, Washington. Pediatrics. 1997;100(5):850-5. PubMed
Grayston JT, Kuo CC, Campbell LA, Wang SP, Jackson LA. Chlamydia pneumoniae and cardiovascular disease. Cardiologia. 1997;42(11):1145-51. PubMed
Jackson LA, Campbell LA, Kuo CC, Rodriguez DI, Lee A, Grayston JT. Isolation of Chlamydia pneumoniae from a carotid endarterectomy specimen. J Infect Dis. 1997;176(1):292-5. PubMed
Jackson LA, Campbell LA, Schmidt RA, Kuo CC, Cappuccio AL, Lee MJ, Grayston JT. Frequency of detection of Chlamydia pneumoniae in cardiovascular atheroma: evaluation of the innocent bystander hypothesis. Am J Pathol. 1997;150(5):1785-90. PubMed
The investigational vaccine is in the third phase of trials and targets flu strains expected to circulate this winter.
KPWHRI researchers analyzed data from more than 640,000 vaccine doses to understand risk of severe reactions.
Encouraging immune-response and safety data emerge from preliminary human test of genetically attenuated parasite vaccine.
IDCRC study finds rapid decline in vaccine-boosted neutralizing antibodies against Omicron variant BA.5
Seattle NPR affiliate KUOW-FM, April 8, 2021
People, March 4, 2021